InsiderTrades.com logo
This Bull Market Indicator called NVDA at $116
From WealthPress   |   Ad
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
All you have to do is follow this link here
Rebecca Taub net worth and biography
  • Phone
  • Email
  • Website

Rebecca Taub Biography and Net Worth

Director, Founder, Chief Medical Officer and President of Research & Development of Madrigal Pharmaceuticals
Dr. Taub has more than 20 years of experience leading drug development, including roles as Senior Vice President of R&D at VIA Pharmaceuticals, Vice President of Metabolic Disease Research at Hoffmann-La Roche, and leadership roles at Bristol Myers Squibb and DuPont Pharmaceuticals. She was also tenured Professor of Genetics and Medicine at the University of Pennsylvania and a Howard Hughes Investigator.

What is Rebecca Taub's net worth?

The estimated net worth of Rebecca Taub is at least $145.54 million as of April 8th, 2024. Dr. Taub owns 458,999 shares of Madrigal Pharmaceuticals stock worth more than $145,543,993 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Taub may own. Additionally, Dr. Taub receives a salary of $939,830.00 as Director, Founder, Chief Medical Officer and President of Research & Development at Madrigal Pharmaceuticals. Learn More about Rebecca Taub's net worth.

How old is Rebecca Taub?

Dr. Taub is currently 72 years old. There are 5 older executives and no younger executives at Madrigal Pharmaceuticals. Learn More on Rebecca Taub's age.

What is Rebecca Taub's salary?

As the Director, Founder, Chief Medical Officer and President of Research & Development of Madrigal Pharmaceuticals, Inc., Dr. Taub earns $939,830.00 per year. Learn More on Rebecca Taub's salary.

How do I contact Rebecca Taub?

The corporate mailing address for Dr. Taub and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on Rebecca Taub's contact information.

Has Rebecca Taub been buying or selling shares of Madrigal Pharmaceuticals?

Rebecca Taub has not been actively trading shares of Madrigal Pharmaceuticals over the course of the past ninety days. Most recently, Rebecca Taub sold 2,676 shares of the business's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $245.99, for a transaction totalling $658,269.24. Following the completion of the sale, the chief marketing officer now directly owns 458,999 shares of the company's stock, valued at $112,909,164.01. Learn More on Rebecca Taub's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 2 times. They purchased a total of 145,509 shares worth more than $29,933,517.51. During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 193,584 shares worth more than $42,301,962.98. The most recent insider tranaction occured on November, 1st when Director Richard S Levy sold 5,000 shares worth more than $1,504,700.00. Insiders at Madrigal Pharmaceuticals own 22.8% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 11/1/2024.

Rebecca Taub Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2024Sell2,676$245.99$658,269.24458,999View SEC Filing Icon  
4/5/2024Sell27,506$243.36$6,693,860.16458,999View SEC Filing Icon  
4/3/2024Sell27,845$245.14$6,825,923.30458,999View SEC Filing Icon  
6/11/2018Sell73,526$287.46$21,135,783.96View SEC Filing Icon  
See Full Table

Rebecca Taub Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Rebecca Taub's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $317.09
Low: $310.84
High: $323.99

50 Day Range

MA: $246.71
Low: $202.48
High: $354.85

2 Week Range

Now: $317.09
Low: $168.25
High: $368.29

Volume

277,156 shs

Average Volume

662,765 shs

Market Capitalization

$6.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
When it comes to NVDA… “acceleration cycles” are the key
From DTI   |   Ad
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Use this link to see Nvidia Unchained right away!